Breccia M - Search Results

1

The Economic Burden of Chronic Myeloid Leukemia in Patients with Later Lines: Findings from a Real-World Analysis in Italy.

Breccia M, Chiodi F, Nardozza AP, Valsecchi D, Perrone V, Sangiorgi D, Giacomini E, Rendace MC, Coco P, Premoli E, Degli Esposti L. Breccia M, et al. Adv Ther. 2023 Mar;40(3):961-974. doi: 10.1007/s12325-022-02398-6. Epub 2022 Dec 23. Adv Ther. 2023. PMID: 36562943 Free PMC article.

2

Refining targeted therapies in chronic myeloid leukemia: development and application of nilotinib, a step beyond imatinib.

Breccia M, Alimena G. Breccia M, et al. Onco Targets Ther. 2008 Oct 1;1:49-58. doi: 10.2147/ott.s3291. Onco Targets Ther. 2008. PMID: 21127752 Free PMC article.

3

Systematic review of dasatinib in chronic myeloid leukemia.

Breccia M, Salaroli A, Molica M, Alimena G. Breccia M, et al. Onco Targets Ther. 2013;6:257-65. doi: 10.2147/OTT.S35360. Epub 2013 Mar 27. Onco Targets Ther. 2013. PMID: 23569389 Free PMC article.

4

Bosutinib for Chronic Myeloid Leukemia.

Breccia M, Binotto G. Breccia M, et al. Rare Cancers Ther. 2015;3(1):35-46. doi: 10.1007/s40487-015-0010-y. Epub 2015 Aug 26. Rare Cancers Ther. 2015. PMID: 27182477 Free PMC article. Review.

5

Treatment-free remission in chronic myeloid leukemia.

Molica M, Naqvi K, Cortes JE, Paul S, Kadia TM, Breccia M, Kantarjian H, Jabbour EJ. Molica M, et al. Among authors: breccia m. Clin Adv Hematol Oncol. 2019 Dec;17(12):686-696. Clin Adv Hematol Oncol. 2019. PMID: 31851157

6

On the road to treatment-free remission in chronic myeloid leukemia: what about 'the others'?

Stagno F, Breccia M, Di Raimondo F. Stagno F, et al. Among authors: breccia m. Expert Rev Anticancer Ther. 2020 Dec;20(12):1075-1081. doi: 10.1080/14737140.2020.1829483. Epub 2020 Oct 8. Expert Rev Anticancer Ther. 2020. PMID: 32985290 Review.

7

Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROMEI).

Guglielmelli P, Palandri F, Selleri C, Cilloni D, Mendicino F, Mazza P, Pastore D, Palumbo GA, Santoro M, Pavone V, Impera S, Morelli M, Coco P, Valsecchi D, Passamonti F, Breccia M; ROMEI study group. Guglielmelli P, et al. Among authors: breccia m. Leuk Lymphoma. 2022 Jan;63(1):189-198. doi: 10.1080/10428194.2021.1969388. Epub 2021 Sep 15. Leuk Lymphoma. 2022. PMID: 34521299

8

Chronic Myeloid Leukemia Data at ASH 2021: A Podcast on Patient Unmet Needs and Later-Line Treatment Developments.

Breccia M. Breccia M. Adv Ther. 2022 Mar;39(3):1101-1106. doi: 10.1007/s12325-022-02048-x. Epub 2022 Jan 31. Adv Ther. 2022. PMID: 35099709 Free PMC article. No abstract available.

9

Real-World Analysis of the Therapeutic Management and Disease Burden in Chronic Myeloid Leukemia Patients with Later Lines in Italy.

Breccia M, Chiodi F, Nardozza AP, Valsecchi D, Perrone V, Sangiorgi D, Giacomini E, Rendace MC, Coco P, Premoli E, Degli Esposti L. Breccia M, et al. J Clin Med. 2022 Jun 22;11(13):3597. doi: 10.3390/jcm11133597. J Clin Med. 2022. PMID: 35806885 Free PMC article.

10

Activity and safety of dasatinib as second-line treatment or in newly diagnosed chronic phase chronic myeloid leukemia patients.

Breccia M, Alimena G. Breccia M, et al. BioDrugs. 2011 Jun 1;25(3):147-57. doi: 10.2165/11591840-000000000-00000. BioDrugs. 2011. PMID: 21528941 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

575 results

Search Page